Writing the Actions Taken for Safety Reasons Section in a PBRER
Introduction
The "Actions Taken for Safety Reasons" section documents important measures implemented during the reporting interval in response to safety concerns. Although this section is relatively concise, it provides regulators with valuable insight into how emerging safety information has already influenced regulatory decision-making and pharmacovigilance activities.
The purpose of this section is not merely to list regulatory actions. Rather, it should provide sufficient information for assessors to understand what action was taken, why it was taken and how it relates to the subsequent scientific discussions presented elsewhere in the PBRER. Actions described here frequently influence later discussions regarding identified risks, signal evaluations, product information updates and the integrated benefit-risk assessment.
Authors should therefore regard this section as an important bridge between regulatory history and scientific evaluation. Every significant action described should be reflected consistently throughout the remainder of the report where appropriate.
Regulatory Basis
ICH E2C(R2) requires the Marketing Authorisation Holder to summarise significant actions taken for safety reasons during the reporting interval. Within the European Union, these expectations are implemented through GVP Module VII.
The emphasis is on actions taken because of safety concerns. Routine administrative changes, commercial decisions unrelated to safety and procedural updates that do not arise from evaluation of safety information generally do not belong in this section.
Regulatory Basis
ICH E2C(R2): Actions Taken for Safety Reasons.
EMA Good Pharmacovigilance Practices (GVP) Module VII.
Purpose of this Section
This section provides regulators with a chronological overview of important safety-related actions affecting the medicinal product during the reporting interval.
These actions may include changes initiated by the Marketing Authorisation Holder, requested by regulatory authorities or implemented jointly following scientific review. Regardless of who initiated the action, the objective is to provide context for the evolving benefit-risk assessment.
The section also demonstrates how important safety information has been translated into regulatory action where appropriate. It therefore provides an important link between pharmacovigilance activities and regulatory decision-making.
The emphasis should remain on actions that materially influence understanding or management of the medicinal product's safety profile rather than documenting every operational activity performed during the reporting interval.